58 results about "Small intestine permeability" patented technology

The invention relates to the field of ulcerative colitis, and discloses a multi-parameter monitoring system for evaluating the intestinal barrier function of ulcerative colitis, which is used for realizing the goal of automatically adjusting a treatment scheme according to a monitoring result by constructing a closed-loop feedback treatment system. According to the invention, by designing the nanoprobe of which the surface is modified with a specific binding element and combining with a swallowing capsule endoscopy, real-time imaging and molecular level dynamic tracking of the intestinal barrier are realized, genetically engineered bacteria are constructed to quantify intestinal permeability abnormality and local inflammation level, and an intestinal barrier function damage score and a disease progress prediction result are output; individual monitoring is achieved through transfer learning, ultrasonic elastography, optical coherence tomography, wearable equipment for measuring intestinal electric field impedance spectroscopy and other technologies are adopted, an intestinal wall mechanics-electrophysiology composite parameter set is obtained, and the evaluation accuracy is improved.

The invention belongs to the technical field of biological medicine, and particularly relates to application of garlic polysaccharide in preparation of a product for repairing intestinal injury caused by constipation. An embodiment verifies that the garlic polysaccharide can effectively repair intestinal physical, chemical and immune barrier injuries caused by constipation, and by up-regulating expression of tight junction proteins (such as ZO-1 and Occludin) and reducing expression of Claudin-1, the garlic polysaccharide can enhance tight junction between intestinal epithelial cells and reduce intestinal permeability; besides, the garlic polysaccharide can promote secretion of intestinal mucoprotein and enhance the protection function of the intestinal mucous layer by up-regulating expression of MUC2 and MUC4 genes. The invention discloses a multi-aspect action mechanism of the garlic polysaccharide in repairing intestinal injury caused by constipation, and the garlic polysaccharide is expected to become a novel intestinal repairing agent for treating constipation and related complications thereof.

We are disclosing derivatives of 5-hydroxylated polymethoxyflavones. The derivatives offer enhanced oral bioavailability and improved intestinal permeability. The derivatives of the invention release the biologically active 5-hydroxylated polymethoxyflavones that are activated by chemical or enzymatic processes in the GI Tract. The derivatives are constructed as bioreversible prodrugs containing the bioactive molecules covalently linked with lipids like fatty acids, glycerides or phospholipids. The derivatives are useful against inflammatory conditions and aging. Formulations including the derivatives are also disclosed.

The invention relates to the technical field of medicines for treating intestinal ischemia-reperfusion injury, and discloses a medicine for treating intestinal ischemia-reperfusion injury and a preparation method thereof. Comprising 10 to 25 parts of rosmarinic acid, 5 to 15 parts of betaine, 3 to 10 parts of glutamine, 10 to 25 parts of salvianolic acid B, 5 to 15 parts of astragaloside, 3 to 10 parts of ginsenoside Rg1, 2 to 8 parts of curcumin, 5 to 12 parts of ophiopogon japonicus polysaccharide, 2 to 6 parts of notoginsenoside R1, 3 to 7 parts of total flavonoids of oldenlandia diffusa and 4 to 9 parts of angelica sinensis polysaccharide. The medicine disclosed by the invention can be used for relieving intestinal edema, repairing oxidative injury, clearing excessive ROS, improving SOD activity, blocking oxidative stress injury, inhibiting epithelial cell apoptosis, reducing intestinal permeability and maintaining mucous membrane integrity, and has an excellent treatment effect on intestinal ischemia reperfusion injury.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

The invention discloses an in-vitro drug intestinal permeability determination method based on a high-flux barrier chip, and belongs to the technical field of microfluidics and organ chips. The high-flux barrier chip adopts a three-layer structural design of a pore plate layer, a porous membrane layer and a channel layer; the porous membrane not only realizes physical separation of the pore plate layer and the channel layer, but also undertakes the core function of interlayer substance exchange, and by matching with a gravity flow driving system provided by the swing table, the fluid dynamic characteristics in the chip are guaranteed. The hole pitch of the chip is strictly matched with the standard of a commercialized pore plate, and the chip can be directly compatible with various conventional analytical instruments and has good universality. The method is suitable for determining the intestinal permeability of the passive transport compound which can be absorbed by intestinal cells. Compared with the prior art, the human intestinal cells are adopted to construct the chip model, animal experiments do not need to be carried out, related ethical disputes are thoroughly avoided, the whole operation process is simple and easy to implement, and the detection time is greatly shortened.

The invention belongs to the technical field of intestinal health care, and relates to a composition containing a milk fat globular membrane and application of the composition. The composition comprises the following components in parts by weight: 0.1 to 0.4 part of a milk fat ball membrane, 0.4 to 2.4 parts of fructo-oligosaccharide, 0.1 to 1 part of xylooligosaccharide, 0.1 to 0.5 part of stachyose and 0.1 to 0.5 part of metabiotics. The composition can increase beneficial bacteria, inhibit growth of harmful bacteria and increase intestinal peristalsis; the intestinal permeability is regulated; meanwhile, the level of tight junction protein and mucoprotein in the intestinal tract is adjusted, and the intestinal tract barrier is enhanced; the intestinal inflammation level can also be regulated. The composition improves intestinal health through multiple targets, and has a remarkable effect on improving intestinal problems such as constipation and inflammatory bowel diseases; meanwhile, depression and anxiety mood caused by intestinal problems can be relieved, the life quality is improved, and the traditional Chinese medicine composition is more beneficial to overall health of organisms and can be taken for a long time.

The invention discloses a compound and application thereof in preparation of a medicine for treating Alzheimer disease. The invention provides a method for constructing a disease animal model by using N-oleoyldopamine (OLDA) and application of the model in drug screening and animal experiment research. The animal model comprises at least one animal model of neurodegenerative diseases, intestinal permeability diseases and inflammatory diseases. According to the application, based on OLDA, it is found that the compound has new application in the aspects of neurodegenerative diseases, intestinal permeability diseases and inflammatory diseases, and based on OLDA, the compound which plays a certain role in treating the diseases is screened out.

This invention discloses the application of a composition in the preparation of foods or medicines that reduce blood lead levels, belonging to the field of food or pharmaceutical applications. The composition is for improving intestinal microecology, comprising inulin, galactooligosaccharides, polydextrose, and water-insoluble dietary fiber, wherein the weight ratio of inulin, galactooligosaccharides, polydextrose, and water-insoluble dietary fiber is 25:25:20:30, and the composition is taken immediately after being dissolved in warm water before meals. This invention, through the rational combination of water-insoluble dietary fiber and functional polysaccharides, adjusts the release rate of nutrients in the intestine, slows down digestion, absorbs and eliminates toxic substances from food, reduces intestinal permeability, and simultaneously possesses the functions of water absorption and swelling, gradient adhesion, mechanical isolation, mesh adsorption, ion exchange, and microbial regulation, providing a favorable environment and food for the growth of intestinal microorganisms, and effectively reducing blood endotoxins and blood lead levels, enhancing immunity, and preventing chronic diseases.

The invention provides a composition for promoting absorption of insoluble drugs and an oral preparation. The composition comprises an andrographolide compound, organic acid, carbonate and cholate. The composition can improve the in-vitro release, intestinal transmittance and oral bioavailability of the indissolvable drug.

The invention provides application of a five-membered heterocycle substituted styrene derivative in preparation of a medicine for treating ulcerative colitis and / or improving intestinal barrier function and the medicine. The five-membered heterocycle substituted styrene derivative disclosed by the invention not only can be used for remarkably relieving symptoms of mouse ulcerative colitis (UC) induced by dextran sodium sulfate (DSS), but also is safe and free from toxic and side effects. The invention also verifies that the five-membered heterocycle substituted styrene derivative has an anti-inflammatory effect, can improve the barrier function of the intestinal tract, and can inhibit the increase of the permeability of the intestinal tract caused by ulcerative colitis. According to the application, the treatment effect of the five-membered heterocycle substituted styrene derivative on ulcerative colitis and the improvement effect on the intestinal barrier function are defined from the action mechanism, and the activation of an aromatic receptor can also improve the intestinal immune function; the invention provides a new therapeutic target and theoretical basis for fundamental research and clinical treatment of ulcerative colitis.

The invention discloses a feed additive for improving pathogen resistance and intestinal injury of high-fat fed fishes and application of the feed additive, and belongs to the technical field of fish feed. The feed additive is indole-3-propionic acid, and the application of the feed additive is that IPA is added into a high-fat feed according to the addition amount of 20-160 mg / kg. Experiments find that IPA with different concentrations can significantly improve the aeromonas hydrophila infection resistance of tilapia fed with high fat, enhance the intestinal immune enzyme activity, improve the intestinal permeability, enhance the intestinal antioxidant ability and relieve intestinal inflammation. The IPA disclosed by the invention can be used as a novel feed additive, can effectively relieve the problems of pathogen resistance reduction and intestinal injury of high-fat fed fishes, and has a good application prospect.

The present invention relates to a use of Bacillus-derived superoxide dismutase for preventing or treating kidney injury. More specifically, the present invention relates to a pharmaceutical composition or a therapeutic method for prevention or treatment of kidney injury. The composition and method according to the present invention exhibit at least one effect selected from the group consisting of a change in intestinal microbial composition, a reduction in intestinal epithelial cell death, a reduction in intestinal permeability, a reduction in oxidative stress in the kidney, an alleviation of tubular injury, and an improvement in kidney function, and thus can be effectively used for preventing or treating kidney injury.

The present invention relates to a Lactobacillus reuteri, and use, composition, drug and food thereof. The Lactobacillus reuteri has an accession number of CGMCC No. 21577, can improve intestinal flora disorder, reduce intestinal injury, improve intestinal permeability and promote immune system recovery, and has effects of treating or preventing allergic reactions of nervous system-related diseases such as autism, hyperactivity, tics, depression, etc.

The present invention relates to an active ingredient consisting of the following molecules: acetic acid, butyric acid, lactic acid and propionic acid, and / or salts and / or esters and / or anhydrides of one or more of these molecules, and optionally at least one pharmaceutically acceptable excipient, to a composition comprising said active ingredient, and to a pharmaceutical composition comprising said active ingredient. And to the use thereof, in particular as a medicament.

Pharmacological experiment results show that in a chronic alcoholic intestinal injury model, total lignans of schisandra chinensis can reduce histological injury of intestinal tracts of mice, relieve oxidative injury of small intestines, improve tight connection of the intestinal tracts through a RhoA / ROCK1-MLCK-MLC pathway, improve the intestinal tracts and improve the intestinal tracts, so that the total lignans of schisandra chinensis can be used for preventing and treating chronic alcoholic intestinal injury. The composition can improve intestinal wall villus integrity, reduce intestinal permeability and regulate intestinal flora disorder, so that alcoholic intestinal injury is improved.

The invention provides an oral administration composition combining a cytarabine amino-acid ester medicine and chidaridine, and belongs to the field of medicines. The invention provides a cytarabine amino-acid ester composition. The cytarabine amino-acid ester composition comprises cytarabine amino-acid ester or salt of the cytarabine amino-acid ester and chidaridine. In one aspect, the pharmaceutical composition of the present invention relates to a method for increasing the oral bioavailability of cytarabine by increasing the permeability of the small intestine. The compound has a more excellent effect of inhibiting the activity of cytidine deaminase, and the metabolism of cytarabine is reduced. The specific proportion effect of the pharmaceutical composition disclosed by the invention is superior to the effect of the combination of the non-cytarabine amino-acid ester prodrug and the chidaridine.

The use of a probiotic, in particular an Enterococcus faecium strain named SF68, for the treatment of disorders characterized by alterations of the intestinal mucosa, particularly inflammations associated with altered intestinal permeability is described.

The present disclosure relates to a composition containing parsnip extract as an active ingredient which reduces the downregulation of tight junction protein expression, promote the proliferation of beneficial intestinal bacteria, improve the intestinal environment such as maintaining a slightly acidic intestinal environment, and have effects such as reducing intestinal permeability. Therefore, the composition may improve intestinal health and prevent, treat, or improve leaky gut syndrome, and may be used as a material for foods, feeds, pharmaceuticals, or quasi-drugs. Additionally, the composition may have body fat reduction and weight loss activities, reduce the protein expression of lipid metabolism-related factors such as ACC, FAS, SREBP1, ChREBP, G6PD, or C / EBPα, and have effects such as reducing liver weight, reducing blood sugar, reducing ALT or AST levels, reducing insulin resistance, and reducing extent of liver damage. Therefore, the composition may prevent, treat, or improve obesity or a metabolic disease.

The invention relates to liver-targeted lycopene plastid pellets and application thereof, the problems that lycopene is poor in water solubility, easy to oxidize and degrade and the like can be solved through the nanoscale structure of plastid membranes wrapping lycopene of the plastid pellets, and the liver-targeted lycopene plastid pellets serve as a natural delivery system. The plastid pellets can improve the water solubility of lycopene and the resistance to ions, acid, heat and other conditions, have good gastrointestinal stability and intestinal permeability, can effectively deliver lycopene to blood and liver and improve the bioavailability of lycopene, and can be applied to the fields of biological medicine, functional food and the like. In addition, the plastid pellets are derived from natural edible plant tissues, can meet the pursuit of consumers on health without side effects, and have wide development prospects.

Disclosed herein are compositions and methods for treating, improving, reducing, or ameliorating a disease or condition associated with intestinal permeability in a subject wherein the disease or condition associate with intestinal permeability is selected from the group consisting of irritable bowel syndrome-bile acid diarrhea (IBS-BAD). Method disclosed herein may also include providing to a subject a composition comprising at least one fiber source and an effective amount of N-trans-caffeoyltyramine and N-trans-feruloyltyramine.

The invention belongs to the technical field of biomedicine, and particularly relates to application of polypeptide in preparation of a medicine for treating radioactive intestinal injury. The polypeptide sequence provided by the invention is Thr-Met-Val-Asp-Ala, is called TMVAD small peptide for short, and is subjected to N-terminal acetylation and C-terminal amidation modification. Results of embodiments prove that mouse animal experiments prove that the TMVAD small peptide has a radiation protection effect in an X-ray induced mouse radioactive intestinal injury model, and can significantly improve the survival rate of irradiated mice, reduce the inflammatory factor level of the irradiated mice, improve the intestinal permeability, promote the regeneration of crypt cells and repair the intestinal mucosal barrier. Compared with the existing symptomatic support treatment or non-specific polypeptide control, the TMVAD small peptide has a remarkable radiation protection effect, so that the TMVAD small peptide can be used as a novel and effective radiation protection and radioactive intestinal injury treatment medicine for clinical treatment of radioactive intestinal injury.

This invention relates to the field of pharmaceutical technology, specifically to the application of porcine deoxycholic acid (HDCA) in the preparation of a drug for alleviating colitis. The dosage of HDCA is 50-200 mg / kg body weight / day. The colitis referred to is DSS-induced colitis, inflammatory bowel disease, or ulcerative colitis. Administration is by gavage. The drug alleviates colitis by promoting the proliferation of intestinal stem cells and / or repairing intestinal barrier function. This method can reverse the decrease in food intake and body weight in mice under DSS, reduce their disease activity index, and alleviate the problem of DSS-induced colon shortening in mice; simultaneously, HDCA also promotes the proliferation of intestinal stem cells, repairs intestinal permeability, and alleviates DSS-induced damage to the intestinal mucosal barrier function in mice. It can inhibit the expression of intestinal inflammation-related genes in mice, alleviating inflammatory complications. It helps to reshape the intestinal flora of mice, especially promoting Akkermansia colonization and alleviating intestinal barrier damage.

The present invention relates to a Lactobacillus reuteri, and use, composition, drug and food thereof. The Lactobacillus reuteri has an accession number of CGMCC No. 21577, can improve intestinal flora disorder, reduce intestinal injury, improve intestinal permeability and promote immune system recovery, and has effects of treating or preventing allergic reactions of nervous system-related diseases such as autism, hyperactivity, tics, depression, etc.

The present invention belongs to the field of biomedicine, and particularly relates to the application of 5-O-methylvisamminol glycoside in the preparation of products for treating hyperuricemia. The present invention has detected that 5-O-methylvisamminol glycoside, a new inhibitor of CNT2, can reduce the absorption of dietary purine nucleosides in the intestine by inhibiting CNT2, thereby exerting a uric acid-lowering effect and protecting against uric acid-related diseases. At the cellular level, 5-O-methylvisamminol glycoside can competitively bind to CNT2 and inhibit adenosine transport. At the animal level, the uric acid concentration in mice treated with 5-O-methylvisamminol glycoside is more stable and can return to the initial uric acid range more quickly. It can relieve liver and kidney injuries caused by hyperuricemia and improve intestinal permeability at the same time. The solution of the present invention provides a design idea for the design, synthesis and development of novel intestinal purine absorption inhibitors, and provides a new target for the clinical treatment of hyperuricemia.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

The invention relates to lactobacillus amylovorans and an application thereof in intestinal diseases, the lactobacillus amylovorans (LA) is named as lactobacillus amylovorans QC1H, is preserved in China Center for Type Culture Collection on March 28, 2023, and has a preservation number of CCTCC NO: M2023427, the lactobacillus amylovorans and / or a fermentation product thereof can significantly improve the ratio of mouse intestinal villus length to crypt depth, and the lactobacillus amylovorans and / or the fermentation product thereof can significantly improve the intestinal villus length and crypt depth of mice. The compound has the advantages of reducing mouse ileum enteritis factor expression, improving ileum tight junction protein expression and reducing intestinal permeability, and has important application significance and value in preparation of a therapeutic agent for preventing and treating enteritis caused by aflatoxin B1 (AFB1).

The present application relates to the field of biological medicine and functional food, and discloses a kind of nutrition composition based on marine shrimp peptide for anti-obesity and improving metabolic syndrome;Including: Chinese tube whip shrimp peptide active component and pharmaceutically acceptable adjuvant, the Chinese tube whip shrimp meat protein is used as raw material, and the Chinese tube whip shrimp meat protein is prepared by alkaline protease enzymolysis, and the Chinese tube whip shrimp meat protein contains peptide segment with molecular weight less than 1 kDa, and APPPPP, HPPPP and MPLPP can be detected.The pharmaceutical composition can reduce the weight and fat tissue weight under the state of obesity, improve dyslipidemia, abnormal liver function and liver steatosis, reduce oxidative stress level, improve intestinal mucosal barrier damage and intestinal permeability increase, and regulate intestinal flora structure change.The active component in the present application is clear in origin, and the preparation process is clear, has the synergistic effect from lipid metabolism regulation, liver protection to intestinal barrier improvement, and can be used for preparing medicine for preventing or treating obesity and improving metabolic syndrome.

The application discloses a kind of film type L-arginine-alpha-ketoglutarate salt sustained-release particles and its preparation method and application.The sustained-release particles include internal core material and external wall material, internal core material is L-arginine-alpha-ketoglutarate salt, external wall material is homogeneous complex matrix of stearic acid and sodium alginate, and the mass ratio of core material and wall material is 7:3 to 8:2.The sustained-release particles are obtained by stearic acid-sodium alginate complex wall material cold spray coating L-arginine-alpha-ketoglutarate salt, realize the synergistic effect of gastric acid tolerance and intestinal target release.Under 0.75%-1.00% additive dose, the sustained-release particles can significantly repair fish intestinal physical barrier, up-regulate tight junction protein and oligopeptide transporter expression, reduce serum intestinal permeability markers, and simultaneously activate muscle mTOR signaling pathway, promote collagen deposition, reduce drip loss rate, and comprehensively improve fish intestinal health and muscle quality.